louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04243811: Efficacy of Low Level Laser Therapy on İnjection Pain
Official title: Efficacy of Low Level Laser Therapy in the Management of Injection Pain During Supraperiosteal Anesthesia in Children: A Randomize Clinical Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Pediatric Anesthesia
Low Level Laser Theraphy
Keywords: pediatric patient
injection pain
lllt
Lead sponsor: Okan University
Sponsor class: OTHER
First posted: 2020-01-28
Enrollment: 0
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to compare the pain during needle insertion and injection in supraperiosteal anesthesia with either topical anesthesia (control) or LLTT (experimental).


Eligibility criteria: Inclusion Criteria:

In need of treatment of right and left molar teeth of maxilla,

* Does not have any systemic disorder,
* High level of communication that can provide logical answers to the questions we ask
* With parental consent,
* Volunteers who want to participate in the research
* 6-12 years old patients who are compatible with routine dental treatments in the pediatric clinic

Exclusion Criteria:

* No need for treatment of right and left molar teeth of maxilla,
* Has a systemic condition
* Low level of communication that cannot provide reasonable answers to the questions we ask
* Without parental consent
* Do not want to participate voluntarily in the research
* Do not attend a check-in
* Patients not in the 6-12 age group

Primary outcomes:
measure: Wong-Baker Faces Pain Rating Scale (PRS)
timeFrame: 1 year
measure: Face, Legg, Cry, Consolability Scale (FLACC)
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Okan University Faculty of Dentistry
Study officials:
References:
Clinical trial NCT05689411: The Effect of The Musical Toy Used During Peripheral Vascular Access on Children's Pain, Fear And Parents' Satisfaction
Official title: The Effect of The Musical Toy Used During Peripheral Vascular Access on Children's Pain, Fear And Parents' Satisfaction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Child, Only
Parents
Keywords: Pain
Fear
Children
Parent
Lead sponsor: T.C. ORDU ÜNİVERSİTESİ
Sponsor class: OTHER
First posted: 2023-01-19
Enrollment: 70
Sex: ALL
Minimum age (years): 3
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled experimental
Primary purpose: SUPPORTIVE_CARE

Brief summary: The research was carried out as a randomized controlled experimental study in order to examine the effects of the child's pain, fear and parent's satisfaction before and after vascular access with a musical toy-xylophone, which is used as a distraction technique for the preparation of the 3-6 year old child hospitalized in the pediatric clinic.

Detailed description: The population of the study consists of children aged 3-6 years who applied to Durağan Şehit Hakan Tanrıkulu State Hospital Pediatric Service between January 2022 and December 2022 and needed vascular access. The sample of the study consisted of 70 children (control: 35, experiment: 35) who met the case selection criteria. Child and Parent Descriptive Information Form, Child Fear Scale (CFS), Children's Emotional Indicator Scale (CEIS), QUCHER Photographic and Numerical Rating Form (QUCHER), and Nurse-Patient Collaboration Level and Parent Satisfaction Form were used. While the children in the experimental group were playing with a musical toy with their parents, peripheral vascular access was performed.

Eligibility criteria: Inclusion Criteria:

* The child is between 3-6 years old,
* Volunteering of parents and children to participate in the research,
* The child does not come to the hospital with acute pain,

Exclusion Criteria:

* The child has a hearing, vision and mental problem,
* The child and the parent do not understand and speak Turkish easily,
* Absence of a primary caregiver,

Primary outcomes:
measure: Children's Emotional Indicator Scale
timeFrame: 5 minutes before the procedure.
measure: Children's Emotional Indicator Scale
timeFrame: 5 minutes after the procedure.
measure: Child Fear Scale
timeFrame: 5 minutes before and after the procedure.
measure: Child Fear Scale
timeFrame: 5 minutes before the procedure.
measure: Qucher-Photographic and Numerical Rating Scale
timeFrame: 5 minutes before the procedure.
measure: Qucher-Photographic and Numerical Rating Scale
timeFrame: 5 minutes after the procedure.
Secondary outcomes:
measure: Nurse-Patient Cooperation and Patient Parent Satisfaction Form
timeFrame: 5 minutes before the procedure.
measure: Nurse-Patient Cooperation and Patient Parent Satisfaction Form
timeFrame: 5 minutes after the procedure.
Other outcomes:
Locations:
city: Ordu
country: Turkey
facility: Dilek alemdar
Study officials:
References:
Clinical trial NCT03193411: Visumax Femtolasik Versus Moria M2 Microkeratome in Myopia
Official title: Visumax Femtolasik Versus Moria M2 Microkeratome in Mild to Moderate Myopia: Efficacy, Safety, Predictability, Aberrometric Changes and Flap Thickness Predictability
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lasik in Myopia
Lead sponsor: Dar Al Shifa Hospital
Sponsor class: OTHER
First posted: 2017-06-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: this is an interventional prospective clinical study which was conducted to evaluate the efficacy, safety, predictability, ocular aberrations, and flap thickness predictability of Visumax femtosecond laser (FSL) compared to Moria M2 microkeratome (MK) in mild to moderate myopia.

Detailed description: This study included 60 eyes who were divided into two groups. Thirty eyes in group (I) in which the flap was created with Visumax FSL, while in group II (30 eyes) the Moria M2 MK was used. Keratometric, refractive, and aberrometric measurements were compared preoperatively and 3 months postoperatively. The intraoperative subtraction pachymetry (the SP 100 Handy pachymeter (Tomey, Nagoya, Japan) was used for preoperative pachymetry and flap thickness measurement.

Eligibility criteria: Inclusion Criteria:

* Male and female patients were eligible for the study if they were older than 18 years and younger than 40 years.
* Stable myopia up to -6.0D and astigmatism up to -3.0D determined by manifest refraction for at least 6 months.
* best corrected distance visual acuity of at least 20/20, and stable keratometry after cessa¬tion of soft contact lens wear for at least 2 weeks.

Exclusion Criteria:

* any anterior seg¬ment pathology.
* any form of retinal degeneration. unstable myopia.
* severe dry eye.
* corneal thickness that would have resulted in less than 300 µm residual stromal thickness.
* Patients who had keratoconus or were keratoconus suspects.
* previous ocular sur¬gery.
* a history of herpes zoster ophthalmicus or herpes simplex keratitis.
* a history of a steroid-responsive rise in in¬traocular pressure (IOP) or a preoperative IOP of more than 21 mmHg.
* diabetes mellitus, autoimmune dis¬ease, connective tissue disease, and chronic use of systemic corticosteroid or immunosuppressive therapy were also excluded from the study.

Primary outcomes:
measure: visual outcomes
timeFrame: 6 months
measure: refractive outcomes
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: daralshifa hospital
name: Magda Torky
role: PRINCIPAL_INVESTIGATOR
References:
citation: Torky MA, Al Zafiri YA, Khattab AM, Farag RK, Awad EA. Visumax femtolasik versus Moria M2 microkeratome in mild to moderate myopia: efficacy, safety, predictability, aberrometric changes and flap thickness predictability. BMC Ophthalmol. 2017 Jul 17;17(1):125. doi: 10.1186/s12886-017-0520-5.
Clinical trial NCT03839511: Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study
Official title: Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
First posted: 2019-02-15
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We will enroll up to 8 healthy men or women (goal n=3 completers) in this method development study.

Brief summary: A hyperinsulinemic-hypoglycemic clamp is an experimental procedure, which allows for hypoglycemia to be studied in a safe and controlled manner. The goal of this study is to establish the hyperinsulinemic-hypoglycemic clamp procedure at Pennington Biomedical Research Center in order to apply the knowledge gained to future studies which will determine the efficacy of our biomarker for predicting susceptibility to hypoglycemia. Additionally, our use of continuous glucose monitoring (CGM) during the clamp procedure will provide novel data regarding the accuracy of CGM during hypoglycemic conditions in a controlled research setting.


Eligibility criteria: Inclusion Criteria:

* Healthy male or female
* Ages 18-40 years
* BMI between 20 kg/m2 and 30 kg/m2 (±0.5 kg/m2 will be accepted)
* Medically cleared for participation in the study

Exclusion Criteria:

* History of clinically diagnosed diabetes or a fasting blood glucose \>126 mg/dL
* Average screening blood pressure \>140/90 mmHg
* History of cardiovascular disease
* Pregnant, planning to become pregnant, or breastfeeding
* Based on the investigative team's clinical judgement, a subject may not be appropriate for participation in the study.

Primary outcomes:
measure: Peak Epinephrine Levels
timeFrame: 90 minute interval following initiation of insulin infusion
Secondary outcomes:
measure: CGM Glucose
timeFrame: 90 minute interval following initiation of insulin infusion
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
References:
Clinical trial NCT05220111: Quality of Life 12 Months After Cardiac Surgery
Official title: Quality of Life 12 Months After Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Quality of Life
Keywords: Quality of Life, postoperative
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
Collaborators: name: Tampere University
First posted: 2022-02-02
Enrollment: 1594
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All comers for primary or secondary major cardiac surgery (cabg, valve, aorta or combined procedures)

Brief summary: Cardiac surgical patients entering the hospital for operation were voluntarily recruited to participate a 12 month follow- up of health related quality of life (QOL)

Detailed description: Cardiac surgical patients entering the hospital for operation were voluntarily recruited to participate a 12 month follow- up of health related quality of life based on established QOL measurements with EuroQol quality of life 5 dimensional 3 level (EQ-5D-3L) description system at preoperative, 6 months and 12 months postoperatively. The study started on May 2013 and ended at the end of 2018. The data has been analyzed for publication in 2021. The total number of patients reached 1594.

Eligibility criteria: Inclusion Criteria:

* elective or urgent cardiac surgery (open heart procedure to valves or ascending aorta /arch, on-pump or off-pump surgery to the coronary arteries )
* willingness to participate,
* ability to comprehend Finnish language

Exclusion Criteria:

* emergency surgery (with no time to introduce the study in good time)
* not willing to participate,
* blind or other disturbance in seeing,
* inability to comprehend Finnish language

Primary outcomes:
measure: EQ-Visual Analogue Scale result, preoperative
timeFrame: preoperative
measure: EQ-Visual Analogue Scale result, at 6 months
timeFrame: 6 months after surgery
measure: EQ-Visual Analogue Scale result, at 12 months
timeFrame: 12 months after surgery
measure: Results of preoperative Quality of life dimensions
timeFrame: preoperative
measure: Results of Quality of life dimensions at 6 months after surgery
timeFrame: 6 months after surgery
measure: Results of Quality of life dimensions at 12 months after surgery
timeFrame: 12 months after surgery
Secondary outcomes:
measure: Overall mortality rate
timeFrame: over the follow-up period ranging 3 to 9 years postoperatively
measure: Overall surgical morbidity rate
timeFrame: 0 to 12 months after surgery
Other outcomes:
measure: Re-hospitalization rate
timeFrame: over the follow-up period ranging 3 to 9 years postoperatively
Locations:
Study officials:
affiliation: Head of Department
name: Jari Laurikka, MD,PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03606811: Fluoroscopic &Ultrasonographic Guidance of Superior Hypogastric Plexus Neurolysis in Intractable Pelvic Pain
Official title: The Role of Double Modality " Fluoroscopic &Ultrasonographic " Guidance of Superior Hypogastric Plexus Neurolysis in Treating Intractable Pelvic Cancer Pain: a Comparative Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intractable Pelvic Cancer Pain
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-07-31
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: fluoroscopic group \& includes 30 patients where SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.the double modality group \& includes 30 patients where SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years.
* Intractable pelvic cancer pain (VAS \> 40 mm)
* Pain is refractory to pharmacotherapy (both opioids and adjuvant therapy) or opioids' side effects are not tolerated.

Exclusion criteria

* Local or systemic sepsis.
* Uncorrectable coagulopathy.
* Neuropsychiatric illness.
* History of drug abuse.
* Pregnant or lactating patients.
* Distorted local anatomy.
* Patients who are known to be allergic to the used medications.
* Cardiovascular or respiratory instability.

Primary outcomes:
measure: pain relief will be assessed by VAS
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: NCI, Cairo university
Study officials:
References:
Clinical trial NCT03231111: The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life
Official title: The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lung Cancer
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2017-07-27
Enrollment: 60
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life


Eligibility criteria: Inclusion Criteria:

1. Patients older than 20 years of age.
2. The first time to accept the target drug treatment (Iressa, Tarceva) treatment, diagnosis of lung cancer third or fourth stage of the women.
3. There are computer equipment at home to play the disc.
4. can speak, write, read Chinese, clear consciousness, no cognitive impairment.
5. In the medical center of Taipei, a medical department, medical or surgical clinic for treatment.

Exclusion Criteria:

* none

Primary outcomes:
measure: skindex-29
timeFrame: average of 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT03771911: Quality of Cardiopulmonary Resuscitation Guided by AED vs Telephone-assistance
Official title: Quality of Cardiopulmonary Resuscitation Guided by AED vs Telephone-assistance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiopulmonary Resuscitation
Lead sponsor: Bionorte
Sponsor class: OTHER
Collaborators: name: University of the Basque Country (UPV/EHU)
name: Osakidetza
First posted: 2018-12-11
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of this research is to evaluate and to compare the quality of cardiopulmonary resuscitation (CPR) among untrained laypeople under two different scenarios: automated external defibrillator (AED) guided CPR or dispatcher-assisted CPR. Secondarily, to evaluate the quality of the dispatcher-assisted instructions provided from the emergency call center.

Detailed description: A simulation study will beperformed. 42 volunteers selected by non-probabilistic sampling will be randomized in two scenarios of cardiac arrest on mannequin: (A) AED-guided CPR and (T) dispatcher-assisted CPR. Simulations last 9 minutes. The quality of CPR will be evaluated by metric monitoring of the chest compressions and timing of actions. A peer's content analysis of the telephone instructions will be performed using a checklist.

Eligibility criteria: Inclusion Criteria:

* untrained laypeople
* Volunteers

Exclusion Criteria:

* Pregnants, leg/arm injuried people, chronic back pain.

Primary outcomes:
measure: Cardiopulmonary resuscitations strated
timeFrame: 9 minutes
Secondary outcomes:
measure: Chest compressions rate
timeFrame: 9 minutes
measure: Chest compressions depth/recoil
timeFrame: 9 minutes
measure: Time under CPR
timeFrame: 8 minutes
measure: Hands on chest
timeFrame: 9 minutes
Other outcomes:
Locations:
city: Bilbao
country: Spain
facility: Hospital de Basurto
state: Bizkaia
Study officials:
affiliation: University of the Basque Country (UPV/EHU)
name: Irrintzi Fernández-Aedo, PhD
role: STUDY_CHAIR
affiliation: Osakidetza
name: Gorka Vallejo-De la Hoz, PhD
role: STUDY_CHAIR
affiliation: Ambuiberica
name: Alejandro Etayo-Sancho, RN
role: STUDY_CHAIR
affiliation: Osakidetza
name: Asier Alonso-Pinillos, RN
role: STUDY_CHAIR
affiliation: Osakidetza
name: Sendoa Ballesteros-Peña, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01207011: Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
Official title: A Randomised, Open-Label Phase 3 Trial Comparing Amrubicin Versus Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Lung Cancer
Lead sponsor: Sumitomo Pharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2010-09-22
Enrollment: 202
Sex: ALL
Minimum age (years): 20
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).


Eligibility criteria: Inclusion Criteria:

* Histological or cytological diagnosis of non-small cell lung cancer (NSCLC)
* 1 or 2 prior chemotherapy regimen including 1 platinum-based chemotherapy
* 20 or older but younger than 75 years of age

Exclusion Criteria:

* Symptomatic brain metastasis
* Interstitial pneumonia or pulmonary fibrosis
* Abnormal cardiac function or myocardial infraction within 6 months before study enrollment
* Active infection

Primary outcomes:
measure: Progression free survival
timeFrame: 3.3 months
Secondary outcomes:
measure: Overall survival
timeFrame: 12 months
measure: response rate (RECIST)
timeFrame: 3 months
measure: Number of Participants with Adverse Events
timeFrame: 4 months
Other outcomes:
Locations:
city: Multiple Locations
country: Japan
facility: 32 Sites
Study officials:
References:
citation: Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2017 Feb 1;28(2):285-291. doi: 10.1093/annonc/mdw621.
Clinical trial NCT06702111: Outcome of Allogeneic Hematopoietic Stem Cell Transplantation
Official title: Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adults: Clinical Outcome and Complications
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hematopoietic Stem Cell Transplant (HSCT)
Keywords: Hematopoietic stem cell transplantation
Prognostic factors
Outcome
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
First posted: 2024-11-22
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients aged 18 years or older who are undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Queen Mary Hospital.

Brief summary: To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.


Eligibility criteria: Inclusion Criteria:

* Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Exclusion Criteria:

* participant who is unable to give informed consent in a prospective cohort.

Primary outcomes:
measure: Overall survival
timeFrame: 5 year
measure: Relapse-free survival
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Department of Medicine, Queen Mary Hospital
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital, Hong Kong
Study officials:
affiliation: Department of Medicine, the University of Hong Kong
name: Harry HS Gill, MBBS, MD, FRCP, FRCPath
role: PRINCIPAL_INVESTIGATOR
References:
citation: Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, Lankester AC, Mohty M, Peffault de Latour R, Snowden JA, Yakoub-Agha I, Kroger N; European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021 Jul;56(7):1651-1664. doi: 10.1038/s41409-021-01227-8. Epub 2021 Feb 23.